Shearman & Sterling has advised the mandated lead arrangers on SYNLAB's pre-IPO crossover financing consisting of €1.2 billion multicurrency term and revolving facilities. The transaction was executed in anticipation of SYNLAB's listing on the Frankfurt stock exchange, which took place on April 30, 2021.
The transaction follows the award-winning 2020 SYNLAB refinancing and debt extension which was the first-ever non-distressed note-to-loan exchange offer.
SYNLAB is a Cinven-backed pre-eminent clinical laboratory services company in Europe. It operates across 35 countries on three continents and undertakes more than 500 million clinical tests for more than 50 million patients annually.